Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

NCT07239245 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
PROCEDURE: Transarterial chemoembolization (TACE)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences